KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Short term Debt (2016 - 2022)

Charles River Laboratories International (CRL) has 15 years of Short term Debt data on record, last reported at $25.0 million in Q4 2024.

  • For Q4 2024, Short term Debt changed N/A year-over-year to $25.0 million; the TTM value through Dec 2024 reached $25.0 million, changed N/A, while the annual FY2024 figure was $25.0 million, N/A changed from the prior year.
  • Short term Debt reached $25.0 million in Q4 2024 per CRL's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $50.2 million in Q4 2020 and bottomed at $2.1 million in Q3 2022.
  • Average Short term Debt over 4 years is $10.4 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Short term Debt: skyrocketed 30.27% in 2020, then plummeted 94.43% in 2021.
  • A 4-year view of Short term Debt shows it stood at $50.2 million in 2020, then tumbled by 94.43% to $2.8 million in 2021, then dropped by 25.62% to $2.1 million in 2022, then surged by 1102.5% to $25.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $25.0 million in Q4 2024, $2.1 million in Q3 2022, and $2.4 million in Q2 2022.